San Francisco, CA, United States of America

Timothy Christian Dunn

This inventor holds 98 USPTO granted patents and 37 published patent applications, plus 4 CIPO patents and 13 EPO patents, primarily in Analyte Monitoring (CPC class A61B5-14532). Top assignees: Abbott Diabetes Care Inc., Cygnus, Inc., Animas Technologies, LLC. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Timothy Christian Dunn. Retrieved from https://idiyas.com/inventor/timothy-christian-dunn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 98 (Patent Applications = 37)

% Patents Active = 98.0

CIPO Patents = 4 (Patent Applications = 16)

EPO Patents = 13 (Patent Applications = 40)

Average Co-Inventor Count = 4.4

ph-index = 23

Forward Citations = 7,838(Granted Patents)

Forward Citations (Not Self Cited) = 7,184(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Encinitas, CA (US) (2002)
Menlo Park, CA (US) (2001 - 2007)
San Francisco, CA (US) (2001 - 2024)

Company Filing History:

87 out of 1,449

Abbott Diabetes Care Inc.

Animas Technologies, LLC

where one patent can have more than one assignee

Years Active: 2001-2026

Loading Chart...

Areas of Expertise:

Analyte Monitoring

Glucose Variability

Insulin Data

Glycemic Control

Physiological Parameters

Sensor Calibration

Meal Assessment

Data Synchronization

Episode Detection

Continuous Glucose Monitoring

Health Devices

User Interface

98 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12699105 - Methods, devices, and systems for adjusting laboratory HBA1C values (2026-08-04),

2. D1131495 - Display screen or portion thereof with graphical user interface (2026-06-23),

3. 12642464 - Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same (2026-06-02),

4. 12633384 - Methods, devices, and systems for adjusting laboratory HbA1c values (2026-05-19),

5. 12629103 - System and method to manage diabetes based on hypoglycemic risk (2026-05-19),

6. 12569191 - Methods, devices, and systems for physiological parameter analysis (2026-03-10),

7. 12569172 - Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same (2026-03-10),

8. 12502102 - Systems, devices, and methods for meal information collection, meal assessment, and analyte data correlation (2025-12-23),

9. 12440173 - Displays for a medical device (2025-10-14),

10. 12440172 - Displays for a medical device (2025-10-14),

11. 12424326 - Systems, devices, and methods for episode detection and evaluation (2025-09-23),

12. 12402841 - Systems and methods for use of insulin information for meal indication (2025-09-02),

13. 12279868 - Optimizing analyte sensor calibration (2025-04-21),

14. 12274549 - Optimizing analyte sensor calibration (2025-04-14),

15. 12178617 - Analysis of glucose median, variability, and hypoglycemia risk for therapy guidance (2024-12-31),

Title: The Innovative Mind of Timothy Christian Dunn

Introduction: Timothy Christian Dunn, based in San Francisco, CA, is an accomplished inventor with an impressive portfolio of 78 patents to his name. His work primarily focuses on advancements in glycemic control and continuous glucose monitoring, which have significant implications for diabetes management and healthcare technology.

Latest Patents: Among his latest innovations are two critical patents: one detailing a method and apparatus for providing glycemic control, which involves systems for therapy management based on monitored glucose data and analysis of current and target HbA1C levels. The second patent involves a display screen or a portion thereof featuring a graphical user interface designed for continuous glucose monitoring, enhancing user experience and accessibility in diabetes care.

Career Highlights: Timothy has made substantial contributions to the field while working with notable companies, including Abbott Diabetes Care Inc. and Cygnus, Inc. His experience at these organizations reflects his deep commitment to developing technologies that address pressing health challenges faced by millions.

Collaborations: Throughout his career, Timothy has collaborated with other brilliant minds in the field, including coworkers Gary Alan Hayter and Wesley Scott Harper. Their collective efforts have driven innovation and fostered advancements in diabetes management solutions.

Conclusion: Timothy Christian Dunn's extensive experience and innovative mindset have cemented his position as a leading inventor in the domain of glycemic control technologies. His patents not only showcase his creativity and engineering prowess but also emphasize the importance of improving healthcare systems for better patient outcomes. Through continued collaboration and ingenuity, Dunn's contributions will inspire future developments in the medical field.

Profile summary based on public USPTO records.